TY - JOUR
T1 - Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension
AU - Hoeper, Marius M.
AU - Barberà, Joan Albert
AU - Channick, Richard N.
AU - Hassoun, Paul M.
AU - Lang, Irene M.
AU - Manes, Alessandra
AU - Martinez, Fernando J.
AU - Naeije, Robert
AU - Olschewski, Horst
AU - Pepke-Zaba, Joanna
AU - Redfield, Margaret M.
AU - Robbins, Ivan M.
AU - Souza, Rogério
AU - Torbicki, Adam
AU - McGoon, Michael
N1 - Funding Information:
Dr. Hoeper has received grants from Actelion, Bayer Schering, and Encysive and travel accommodations and speakers' honoraria from Actelion, Encysive, GlaxoSmithKline, Lung Rx, Pfizer, and Schering, and has served as a consultant to Actelion, Bayer Schering, Encysive, GlaxoSmithKline, and Lung Rx. Dr. Barberà has received honoraria and research funds from Actelion, Bayer Schering, GlaxoSmithKline, and Pfizer. Dr. Channick has received consulting and speaker fees and research grants from Actelion, Gilead, Pfizer, and United Therapeutics. Dr. Hassoun has received research grants from Actelion (Cotherix), the National Institutes of Health, the National Heart, Lung, and Blood Institute, and United Therapeutics. Dr. Lang has served as a consultant to Actelion, AOP Orphan Pharmaceuticals, Bayer Schering, Encysive, GlaxoSmithKline, Pfizer, and United Therapeutics. Dr. Manes reports no conflicts of interest. Dr. Martinez has served on speakers' bureaus for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and VoxMedic; advisory boards for AstraZeneca, Forest/Almirall, Genzyme, GlaxoSmithKline, Mpex, Novartis, Nycomed, Schering-Plough, Talecris, and Roche; steering committees for Actelion, Gilead, GlaxoSmithKline, Johnson & Johnson (Centocor), and UBC; and as a primary investigator for Actelion, Altana/Nycomed, Boehringer Ingelheim, and the National Institutes of Health. Dr. Naeije has received research grant support from Actelion, Encysive, and Pfizer, and has served as a consultant and/or steering committee member for Actelion, Encysive, Lung Rx, MondoBIOTECH, and United Therapeutics. Dr. Olschewski has received university grants from Deutsche Forschungsgemeinschaft, Österreichische Nationalbank, and European Union Framework 5 and 6; has received pharmaceutical grants from Actelion, Bayer Schering, Encysive, and Unither Pharmaceuticals; has received travel accommodations and speaker's honoraria from Actelion, Encysive, Gilead (Myogen), Pfizer, Schering, and Unither; and has served as a consultant to Bayer Schering, Gilead (Myogen), GlaxoSmithKline, and Unither. Dr. Pepke-Zaba has received speaker's honoraria from Actelion, Bayer Schering, Encysive, and United Therapeutics, and has served on an advisory board for Actelion. Dr. Redfield has received study drug for research from Pfizer and has served as a consultant to Novartis. Dr. Robbins has received grant/research support from Actelion, BioMarin, Gilead, Pfizer, and United Therapeutics, and has served on advisory boards, steering committees, and/or speakers' bureaus for Actelion, Gilead, and Lung Rx. Dr. Souza has received consulting fees from Actelion; lecture fees from Actelion and Pfizer; and travel support from Gilead (Myogen). Dr. Torbicki has served as a consultant for Eli Lilly, GlaxoSmithKline, and mondoBIOTECH; has received honoraria from Bayer Schering, Eli Lilly, and Sanofi-Aventis; and has conducted research supported by Bayer Schering, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, mondoBIOTECH, and Pfizer. Dr. McGoon has received grant support from Gilead and consulting fees from Actelion, Gilead, Lung Rx, and Medtronic, and has served on Data Safety and Management Board/Clinical Endpoint Committees for Actelion and Gilead.
PY - 2009/6/30
Y1 - 2009/6/30
N2 - The 4th World Symposium on Pulmonary Hypertension was the first international meeting to focus not only on pulmonary arterial hypertension (PAH) but also on the so-called non-PAH forms of pulmonary hypertension (PH). The term "non-PAH PH" summarizes those forms of PH that are found in groups 2 to 5 of the current classification of PH, that is, those forms associated with left heart disease, chronic lung disease, recurrent venous thromboembolism, and other diseases. Many of these forms of PH are much more common than PAH, but all of them have been less well studied, especially in terms of medical therapy. The working group on non-PAH PH focused mainly on 4 conditions: chronic obstructive lung disease, interstitial lung disease, chronic thromboembolic PH, and left heart disease. The medical literature regarding the role of PH in these diseases was reviewed, and recommendations regarding diagnosis and treatment of PH in these conditions are provided. Given the lack of robust clinical trials addressing PH in any of these conditions, it is important to conduct further studies to establish the role of medical therapy in non-PAH PH.
AB - The 4th World Symposium on Pulmonary Hypertension was the first international meeting to focus not only on pulmonary arterial hypertension (PAH) but also on the so-called non-PAH forms of pulmonary hypertension (PH). The term "non-PAH PH" summarizes those forms of PH that are found in groups 2 to 5 of the current classification of PH, that is, those forms associated with left heart disease, chronic lung disease, recurrent venous thromboembolism, and other diseases. Many of these forms of PH are much more common than PAH, but all of them have been less well studied, especially in terms of medical therapy. The working group on non-PAH PH focused mainly on 4 conditions: chronic obstructive lung disease, interstitial lung disease, chronic thromboembolic PH, and left heart disease. The medical literature regarding the role of PH in these diseases was reviewed, and recommendations regarding diagnosis and treatment of PH in these conditions are provided. Given the lack of robust clinical trials addressing PH in any of these conditions, it is important to conduct further studies to establish the role of medical therapy in non-PAH PH.
KW - assessment
KW - diagnosis
KW - non-PAH pulmonary hypertension
UR - http://www.scopus.com/inward/record.url?scp=67649613565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649613565&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2009.04.008
DO - 10.1016/j.jacc.2009.04.008
M3 - Review article
C2 - 19555862
AN - SCOPUS:67649613565
SN - 0735-1097
VL - 54
SP - S85-S96
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 1 SUPPL. 1
ER -